/
LGND
$314.22+$10.45 (+3.44%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$6.1B
20M shares
52-week range
$111.72 – $314.80
100% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$178.11
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $251.5M | $120.3M | $163.6M | $241.5M | $196.2M | $131.3M | $167.1M | $268.1M |
| Cost of revenue | $6.3M | $11.3M | $30.4M | $62.2M | $52.8M | $35.0M | $11.1M | $6.6M |
| Gross profit | $245.1M | $108.9M | $133.1M | $179.4M | $143.4M | $96.3M | $156.1M | $261.5M |
| Gross margin | 97.5% | 90.6% | 81.4% | 74.3% | 73.1% | 73.3% | 93.4% | 97.5% |
| R&D | $27.9M | $55.9M | $40.5M | $32.1M | $36.1M | $24.5M | $21.4M | $81.2M |
| Operating income | $163.7M | $807.1M | $37.5M | $103.9M | $3.0M | $11.9M | −$22.6M | $47.2M |
| EBITDA | $238.3M | $876.1M | $56.7M | $142.8M | $81.2M | $100.8M | $40.8M | $192.7M |
| Net income | $143.3M | $629.3M | −$3.0M | $57.1M | −$33.4M | $52.2M | −$4.0M | $124.5M |
| Net margin | 57.0% | 523.2% | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% |
| EPS (diluted) | 5.96 | 31.85 | -0.18 | 3.34 | -1.98 | 2.94 | -0.22 | 6.13 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $288M | $9.06 | $8.75–$9.67 | 6 |
| 2027 | $371M | $11.13 | $9.93–$12.49 | 5 |
| 2028 | $434M | $12.88 | $10.13–$15.13 | 4 |
| 2029 | $511M | $13.81 | $12.58–$15.14 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$43.58
Price
$314.22
Implied downside
-86%
Peer comparison
Ligand Pharmaceuticals Inc.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
www.ligand.com- Employees
- 47
- IPO / List date
- Nov 25, 1994
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds LGND.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2025-12-31 | 4,207 | $795.4K |
| Renaissance Technologiesas of 2024-09-30 | 3,000 | $300.3K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2010-11-19 | 1-for-6reverse |
Recent trades on TradeandTell
No one on the platform has traded LGND yet.
